| Post |
| Pre |
| LA |
|---|
| 2.7 |
| 2.7 |
| ME 1 | ME 2 | ME 3 | ME 4 | ME 5 | ME 6 | ME 7 | ME 8 | ME 9 | ME 10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 1 | 2.3 | - | - | 3.3 |
| - | - | - | - | - | - | 4 | 5 | - | - | 9 |
| Post |
| Pre |
| LO 1 | LO 2 | LO 3 | LO 4 | LO 5A | LO 5B | LO 6 | Total |
|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - |
| AME |
|---|
| 74.3 |
| 151.3 |
| Post |
| Pre |
| LOP 1 | LOP 2 | LOP 3 | LOP 4 | Total |
|---|---|---|---|---|
| - | - | - | - | - |
| - | - | - | - | - |
| central brain |
|---|
| - |
| - |

| ROI Name | ∑ In | % In | log ratio | ∑ Out | % Out |
|---|---|---|---|---|---|
| AME(R) | 223 | 75.1% | 1.03 | 454 | 79.2% |
| Optic-unspecified(R) | 57 | 19.2% | 0.63 | 88 | 15.4% |
| ME(R) | 9 | 3.0% | 1.35 | 23 | 4.0% |
| LA(R) | 8 | 2.7% | 0.00 | 8 | 1.4% |
| upstream partner | # | NT | conns HBeyelet | % In | CV |
|---|---|---|---|---|---|
| HBeyelet (R) | 3 | HA | 40.7 | 45.5% | 0.4 |
| Dm9 (R) | 3 | Glu | 23.3 | 26.1% | 0.6 |
| OA-AL2i3 (R) | 2 | OA | 12.7 | 14.2% | 0.4 |
| aMe5 (R) | 6 | ACh | 4.7 | 5.2% | 0.9 |
| aMe6c (R) | 1 | Glu | 2.7 | 3.0% | 0.0 |
| MeVPMe12 (L) | 2 | ACh | 1.7 | 1.9% | 0.6 |
| aMe6b (R) | 1 | ACh | 1.3 | 1.5% | 0.0 |
| aMe4 (R) | 2 | ACh | 1 | 1.1% | 0.3 |
| l-LNv (R) | 1 | unc | 0.3 | 0.4% | 0.0 |
| Lat3 (R) | 1 | unc | 0.3 | 0.4% | 0.0 |
| Cm35 (R) | 1 | GABA | 0.3 | 0.4% | 0.0 |
| aMe30 (R) | 1 | Glu | 0.3 | 0.4% | 0.0 |
| downstream partner | # | NT | conns HBeyelet | % Out | CV |
|---|---|---|---|---|---|
| aMe6c (R) | 1 | Glu | 134 | 21.5% | 0.0 |
| aMe6b (R) | 1 | ACh | 103.7 | 16.6% | 0.0 |
| aMe6a (R) | 1 | ACh | 87 | 13.9% | 0.0 |
| aMe3 (R) | 1 | Glu | 67 | 10.7% | 0.0 |
| Dm9 (R) | 3 | Glu | 51.7 | 8.3% | 0.1 |
| HBeyelet (R) | 3 | HA | 40.7 | 6.5% | 0.1 |
| aMe5 (R) | 16 | ACh | 26.3 | 4.2% | 0.7 |
| l-LNv (R) | 4 | unc | 26 | 4.2% | 0.5 |
| aMe30 (R) | 2 | Glu | 19.3 | 3.1% | 0.1 |
| aMe10 (R) | 2 | ACh | 9.3 | 1.5% | 0.7 |
| SLP250 (R) | 1 | Glu | 9 | 1.4% | 0.0 |
| OA-AL2i3 (R) | 2 | OA | 8 | 1.3% | 0.3 |
| Cm28 (R) | 1 | Glu | 6 | 1.0% | 0.0 |
| aMe1 (R) | 2 | GABA | 4 | 0.6% | 0.7 |
| MeVP43 (R) | 1 | ACh | 3.7 | 0.6% | 0.0 |
| LT58 (R) | 1 | Glu | 2.7 | 0.4% | 0.0 |
| aMe4 (R) | 6 | ACh | 2.7 | 0.4% | 0.4 |
| MeVC21 (R) | 2 | Glu | 2 | 0.3% | 0.3 |
| MeVC20 (R) | 2 | Glu | 1.7 | 0.3% | 0.6 |
| LoVC23 (L) | 1 | GABA | 1.3 | 0.2% | 0.0 |
| MeLo7 (R) | 4 | ACh | 1.3 | 0.2% | 0.0 |
| Tm5c (R) | 1 | Glu | 1 | 0.2% | 0.0 |
| MeVP40 (R) | 1 | ACh | 1 | 0.2% | 0.0 |
| Lat5 (R) | 1 | unc | 1 | 0.2% | 0.0 |
| aMe12 (R) | 1 | ACh | 1 | 0.2% | 0.0 |
| aMe2 (R) | 2 | Glu | 1 | 0.2% | 0.3 |
| CL125 (R) | 2 | Glu | 1 | 0.2% | 0.3 |
| Cm23 (R) | 1 | Glu | 0.7 | 0.1% | 0.0 |
| MeVPaMe2 (R) | 1 | Glu | 0.7 | 0.1% | 0.0 |
| aMe_TBD1 (R) | 1 | GABA | 0.7 | 0.1% | 0.0 |
| DNp27 (R) | 1 | ACh | 0.7 | 0.1% | 0.0 |
| MeVP7 (R) | 2 | ACh | 0.7 | 0.1% | 0.0 |
| MeVPMe12 (L) | 1 | ACh | 0.7 | 0.1% | 0.0 |
| LA_ME_unclear (R) | 1 | ACh | 0.3 | 0.1% | 0.0 |
| MeVP11 (R) | 1 | ACh | 0.3 | 0.1% | 0.0 |
| T1 (R) | 1 | HA | 0.3 | 0.1% | 0.0 |
| aMe10 (L) | 1 | ACh | 0.3 | 0.1% | 0.0 |
| aMe17a (R) | 1 | unc | 0.3 | 0.1% | 0.0 |
| MeVP2 (R) | 1 | ACh | 0.3 | 0.1% | 0.0 |
| Cm15 (R) | 1 | GABA | 0.3 | 0.1% | 0.0 |
| Cm11a (R) | 1 | ACh | 0.3 | 0.1% | 0.0 |
| MeVP1 (R) | 1 | ACh | 0.3 | 0.1% | 0.0 |
| TmY19b (R) | 1 | GABA | 0.3 | 0.1% | 0.0 |
| MeVP39 (R) | 1 | GABA | 0.3 | 0.1% | 0.0 |
| MeVP21 (R) | 1 | ACh | 0.3 | 0.1% | 0.0 |
| MeVPaMe2 (L) | 1 | Glu | 0.3 | 0.1% | 0.0 |
| MeVPMe7 (L) | 1 | Glu | 0.3 | 0.1% | 0.0 |
| TmY19a (R) | 1 | GABA | 0.3 | 0.1% | 0.0 |
| MeVP4 (R) | 1 | ACh | 0.3 | 0.1% | 0.0 |
| Lat2 (R) | 1 | unc | 0.3 | 0.1% | 0.0 |
| aMe17b (R) | 1 | GABA | 0.3 | 0.1% | 0.0 |
| Cm30 (R) | 1 | GABA | 0.3 | 0.1% | 0.0 |
| Cm35 (R) | 1 | GABA | 0.3 | 0.1% | 0.0 |
| MeVPMe13 (L) | 1 | ACh | 0.3 | 0.1% | 0.0 |